ProCE Banner Activity

Expanding Our Therapeutic Horizons: The Role of GLP-1 Receptor Agonists in Managing CKD in Type 2 Diabetes

Clinical Thought

Explore the latest advancements in managing chronic kidney disease (CKD) in type 2 diabetes with insights from the FLOW trial on GLP-1 receptor agonists, examining their role in slowing CKD progression and addressing cardiovascular risks, as well as practical strategies for integrating these agents into nephrology practice.

Released: October 31, 2024

Expiration: October 30, 2025

Share

Faculty

David Charytan

David Charytan, MD, MSc

Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Kidney Fund

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Disclosure

Primary Author

David Charytan, MD, MSc

Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York

David Charytan, MD, MSc: consultant/advisor/speaker: AstraZeneca; CSL Behring, GlaxoSmithKline, Lilly/Boehringer, Merck, Novo Nordisk; researcher/research support: AstraZeneca, Lilly/Boehringer, Novo Nordisk; data and safety monitoring board/clinical events committee: AstraZeneca, LG Chem.